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Abstract
Background: Antimicrobial resistance of Staphylococcus aureus especially methicillin-resistant S. aureus
(MRSA) continues to be a problem for clinicians worldwide. However, few data on the antibiotic
susceptibility patterns of S. aureus isolates in South Africa have been reported and the prevalence of MRSA
in the KwaZulu-Natal (KZN) province is unknown. In addition, information on the characterization of S.
aureus in this province is unavailable. This study investigated the susceptibility pattern of 227 S. aureus
isolates from the KZN province, South Africa. In addition, characterization of methicillin-sensitive S. aureus
(MSSA) and MRSA are reported in this survey.
Methods: The in-vitro activities of 20 antibiotics against 227 consecutive non-duplicate S. aureus isolates
from clinical samples in KZN province, South Africa were determined by the disk-diffusion technique.
Isolates resistant to oxacillin and mupirocin were confirmed by PCR detection of the mecA and mup genes
respectively. PCR-RFLP of the coagulase gene was employed in the characterization of MSSA and MRSA.
Results: All the isolates were susceptible to vancomycin, teicoplanin and fusidic acid, and 26.9% of isolates
studied were confirmed as MRSA. More than 80% of MRSA were resistant to at least four classes of
antibiotics and isolates grouped in antibiotype 8 appears to be widespread in the province. The MSSA were
also susceptible to streptomycin, neomycin and minocycline, while less than 1% was resistant to
chloramphenicol, ciprofloxacin, rifampicin and mupirocin. The inducible MLSB phenotype was detected in
10.8% of MSSA and 82% of MRSA respectively, and one MSSA and one MRSA exhibited high-level
resistance to mupirocin. There was good correlation between antibiotyping and PCR-RFLP of the
coagulase gene in the characterization of MRSA in antibiotypes 1, 5 and 12.
Conclusion: In view of the high resistance rates of MRSA to gentamicin, erythromycin, clindamycin,
rifampicin and trimethoprim, treatment of MRSA infections in this province with these antibacterial agents
would be unreliable. There is an emerging trend of mupirocin resistance among S. aureus isolates in the
province. PCR-RFLP of the coagulase gene was able to distinguish MSSA from MRSA and offers an
attractive option to be considered in the rapid epidemiological analysis of S. aureus in South Africa.
Continuous surveillance on resistance patterns and characterization of S. aureus in understanding new and
emerging trends in South Africa is of utmost importance.
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Background
Staphylococcus aureus has emerged as one of the most
important human pathogens, and has over the past sev-
eral decades, been a leading cause of hospital and com-
munity-acquired infections [1]. It is associated with a
variety of clinical infections including septicemia, pneu-
monia, wound sepsis, septic arthritis, osteomyelitis and
post-surgical toxic shock syndrome with substantial rates
of morbidity and mortality [2-5]. One of the reasons for
the success of this human pathogen is its great variability,
occurring at different periods and places with diverse
clonal types and antibiotic resistance patterns within
regions and countries. Although infections caused by anti-
biotic-resistant S. aureus bring about serious problems in
the general population, such infections can be particularly
devastating for the very young, the elderly and the immu-
nocompromised [6].
Antimicrobial resistance among nosocomial pathogens is
a significant problem in many countries with severe con-
sequences including increased medical costs, morbidity
and mortality of patients [7]. Since the emergence of S.
aureus strains with resistance to penicillin and methicillin
in 1948 and 1961 [8,9] respectively, it has become a well-
known etiologic agent of a wide variety of infections, and
has assumed increasing importance internationally as a
cause of both nosocomial and community-acquired infec-
tions. Methicillin-resistant S. aureus (MRSA) infections are
additional to the burden of methicillin susceptible S.
aureus (MSSA) and are particularly difficult to treat espe-
cially if they are located at anatomical sites, where antibi-
otic penetration is reduced [10]. Cohort studies of
patients with MRSA bacteremia have reported increased
morbidity, longer hospital length of stay, and higher costs
compared with patients with MSSA bacteremia [4,5,11-
15]. In addition, most MRSA are resistant to a number of
antimicrobial agents [16].
Although data on the prevalence of staphylococcal infec-
tions in Africa are limited, one of the earliest reports of
MRSA in the continent was in South Africa [17]. Studies in
the 1980s and early 1990s on MRSA in South Africa have
also been described [18-20]. However, there is paucity of
data on susceptibility patterns of S. aureus in South Africa
and the prevalence of MRSA in the KwaZulu-Natal (KZN)
province is unknown. For practicing physicians, clinical
microbiologists and public health officials, knowledge of
the local antimicrobial resistance patterns of bacterial
pathogens is essential to guide empirical and pathogen
specific therapy. The recent reports of S. aureus intermedi-
ately resistant to vancomycin and teicoplanin in South
Africa [21,22] also indicate that information on antibiotic
resistance in S. aureus is critical for optimal decisions
regarding hospital formulary and infection control poli-
cies. In addition, characterization of strains is important
in understanding the epidemiology of S. aureus and eval-
uating the effectiveness of infection control and antimi-
crobial prescribing measures [23]. This study reports on
the antibiotic susceptibility and characterization of S.
aureus from clinical samples in KZN, South Africa.
Methods
Study areas
The KwaZulu-Natal province is one of the nine provinces
in South Africa with a population of about 9.3 million
people. A total of 14 provincial hospitals located in seven
districts in KZN province, participated in the study. The
health institutions included four hospitals in the city of
Durban, two, three and five health facilities located in
western, southern and northern KZN, respectively. The
isolates analyzed in this study were obtained in two
phases. The first phase in 2001 (March to August) was part
of a survey on the susceptibility pattern of bacterial path-
ogens obtained from various clinical specimens in health
institutions in KZN. The second phase commenced in
October 2002 to August 2003. Consecutive non-duplicate
S. aureus isolates from clinical samples were obtained
from the microbiology laboratories of these health insti-
tutions.
Microbiological analysis and identification
A total of 233 isolates were obtained in the two phases.
Identification and confirmation of the isolates was con-
ducted by the investigators. They included growth and fer-
mentation on mannitol salt agar, colonial morphology on
nutrient agar, Gram stain and positive results for catalase,
coagulase and DNase tests. The isolates were preserved in
MicroBank (Diagnostic Pro-Lab) and stored at -20°C for
further characterization.
Antibiotic susceptibility testing
The susceptibility testing of isolates to 20 antibiotics was
carried out by the disk diffusion method according to the
National Committee for Clinical Laboratory Standards
(now Clinical Laboratory Standards Institute) guidelines
[24]. The antibiotics (Mast Diagnostics) included penicil-
lin (10 U), ampicillin (10 µg), oxacillin (1 µg), gen-
tamicin (10 µg), kanamycin (30 µg), streptomycin (30
µg), neomycin (30 µg), erythromycin (15 µg), clindamy-
cin (2 µg), tetracycline (30 µg), minocycline (30 µg), tri-
methoprim (2.5 µg), trimethoprim/sulfamethoxazole (25
µg), chloramphenicol (30 µg), ciprofloxacin (5 µg),
fusidic acid (10 µg), rifampicin (30 µg), teicoplanin (30
µg), vancomycin (30 µg) and mupirocin (5 µg and 200
µg). Isolates resistant to oxacillin were also screened
against methicillin (5 µg) and cefoxitin (30 µg). S. aureus
ATCC 25923 was the control strain in every test run. Inter-
pretative zone diameters for resistance to fusidic acid,
neomycin and streptomycin which are not stated in the
CLSI guidelines were considered as follows; ≤ 18 mm –BMC Infectious Diseases 2006, 6:125 http://www.biomedcentral.com/1471-2334/6/125
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fusidic acid [25], ≤ 16 mm – neomycin, and ≤ 14 mm –
streptomycin [16]. The D-test for determining inducible
resistance of clindamycin by erythromycin was also per-
formed, in which erythromycin and clindamycin disks
were placed 15–18 mm apart. A truncated or blunted clin-
damycin zone of inhibition (D-shape) indicated induci-
ble resistance. Constitutive resistance was recognized by a
clindamycin zone diameter of ≤ 14 mm [26]. Growth to
the edge of the 200 µg mupirocin disk and within a 14
mm zone of inhibition with the 5 µg mupirocin disk indi-
cated high and low-level resistance respectively [27]. Fur-
thermore, isolates that expressed phenotypic resistance to
oxacillin were screened for intermediate resistance to van-
comycin and teicoplanin using the E-test macrodilution
method [28].
The resistance rate to each antibiotic was calculated as the
number of resistant isolates divided by the total number
of isolates. Antibiotyping of MSSA and MRSA was based
on the susceptibility patterns to selected antibiotics, repre-
senting various classes of antimicrobial agents. They
included penicillin (β-lactams), gentamicin (aminoglyco-
sides), erythromycin (macrolides), chloramphenicol
(phenicols), tetracycline (tetracyclines), trimethoprim
(dihydrofolate pathway inhibitors), rifampicin (ansamy-
cins), ciprofloxacin (fluoroquinolones) and mupirocin.
Multiresistance was defined as resistance to penicillin
along with at least three classes of antibiotics.
Molecular detection of the nuc, mecA and mupA genes 
by PCR
DNA isolation was carried out according to the method
previously reported [27]. Isolates resistant to oxacillin,
methicillin and cefoxitin by the disk diffusion technique
were confirmed as S. aureus and MRSA by PCR detection
of the nuc and the mecA genes respectively [29,30]. Low
and high-level mupirocin resistant isolates were con-
firmed by their MIC values (E-test) and the detection of
the mupA gene [31]. The PCR conditions and detection of
PCR products were carried out as described previously
[32].
PCR-RFLP of the coagulase gene
Amplification of the 3' end region of the coagulase gene
containing the 81-bp tandem repeats was performed as
described previously [33]. S. aureus ATCC 25923 served as
the positive control in each PCR reaction. Restriction frag-
ment length polymorphisms (RFLPs) of the amplicons
were determined by digestion with AluI (Fermentas, UK)
by a modification of the protocol previously described
[34].
The sizes of the PCR products and of the restriction DNA
digests (RFLPs with respect to the overall number of 81-bp
tandem repeats) were estimated by comparison with a
100 bp molecular size standard marker, visual inspection
and analysis using the GeneTools program (SynGene Bio-
imaging System). The strains were grouped on the basis of
three characteristics of their PCR products, i.e. the pres-
ence of one or two PCR products, their size (s), and the
AluI restriction digest patterns of the PCR products.
Results
A total of 233 consecutive non-duplicate S. aureus isolates
were obtained from clinical samples in 14 health institu-
tions in KZN province, South Africa. Only six isolates
(2.6%) were misidentified as S. aureus. More than 80% of
the total number of isolates was recovered from wound
samples, followed by sputum (4%), otitis media (3.1%)
and blood samples (2.6%).
The antibiotic susceptibility of S. aureus isolates obtained
in KZN province, South Africa is described in Table 1. All
the isolates were susceptible to teicoplanin, vancomycin
and fusidic acid and the proportion of isolates resistant to
streptomycin, neomycin, chloramphenicol, ciprofloxacin
and mupirocin was less than 10%. Penicillin and ampicil-
lin were the least effective antibacterial agents. In addi-
tion, 30% were resistant to erythromycin, clindamycin,
trimethoprim and tetracycline, 28.6% to gentamicin,
24.2% to minocycline and 20.3% to rifampicin.
In addition to full susceptibility to teicoplanin, vancomy-
cin and fusidic acid, the MSSA were susceptible to oxacil-
lin, streptomycin, neomycin and minocycline. A total of
18 MSSA were susceptible to all the antibiotics tested. Fur-
thermore, less than 1% of MSSA were resistant to chlo-
ramphenicol, ciprofloxacin, rifampicin and mupirocin,
while resistance to gentamicin, kanamycin and tetracy-
cline was less than 10%. Of the 19 erythromycin-resistant
MSSA, only one isolate exhibited the constitutive mac-
rolide-lincosamide-streptogramin B (MLSB) resistance
phenotype. The predominant antibiotype among the
MSSA was resistance only to penicillin, which was
observed in 114 isolates (68.7%) (Table 2). In addition,
the proportion of multi-drug resistant MSSA was 3.6% (6
of 166 isolates). Only one MSSA exhibited high-level
resistance to mupirocin.
Resistance to oxacillin, methicillin and cefoxitin was
detected in 61 isolates (26.9%). These isolates were con-
firmed as MRSA by the detection of the mecA gene. A total
of 48 (78.7%) MRSA isolates were recovered from wound
samples, six (9.8%) from sputum, two (3.3%) from otitis
media, and one isolate each from blood samples, urine,
eye-related infections and endotracheal aspirate. No clin-
ical information was available for one MRSA. Susceptibil-
ity testing of MRSA indicated that over 90% of MRSA were
resistant to gentamicin and kanamycin, and 31% were
resistant to streptomycin and neomycin. Only 9.8% ofBMC Infectious Diseases 2006, 6:125 http://www.biomedcentral.com/1471-2334/6/125
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MRSA were susceptible to tetracycline and minocycline
and over 80% were resistant to trimethoprim and trimeth-
oprim/sulfamethoxazole. All the 50 erythromycin-resist-
ant MRSA were positive for inducible MLSB resistance
using the D-test method. The proportion of MRSA resist-
ant to rifampicin, ciprofloxacin and chloramphenicol was
73.8%, 18% and 16.4%, respectively. Overall, 16 isolates
were resistant to mupirocin, of which 14 MRSA exhibited
low-level resistance. This resistance phenotype was con-
firmed by E-test; with MICs values ranging from 8 to 24 µg
ml-1  and one MRSA exhibited high-level resistance to
mupirocin (>1024 µg ml-1).
The antibiotypes of MRSA based on their susceptibility
patterns to various classes of antibacterial agents are illus-
trated in Table 2. MRSA were categorized into 12 antibio-
types, and isolates grouped in type 8 accounted for about
40% of the total number of MRSA. About 87% of MRSA
were resistant to at least four classes of antibiotics and
more than 40% of MRSA studied were resistant to six
classes of antibiotics. In addition, four MRSA were resist-
ant to eight classes of antibiotics. MRSA in antibiotype 1
(resistance to eight classes of antibiotics) were identified
in two hospitals in the city of Durban, and one health
facility in Pietermaritzburg (Western KZN) and Ngwele-
zane (Northern KZN). Furthermore, MRSA classified in
antibiotype 5 (resistance to seven classes of antibiotics)
were noted in two hospitals in the city of Durban and in
Northern KZN. MRSA in antibiotype 8 was detected in 12
of the 14 hospitals studied.
Typing based on PCR-RFLP of the coagulase gene of S.
aureus isolates from South Africa are illustrated in Figures
1 and 2. PCR products of 98 strains (37 MSSA and 61
MRSA) were analyzed and due to the wide range of sizes
of the PCR products, a cut-off value was determined with
a limit of ± 20 bp. Among the MRSA strains, a single
amplicon of 750 bp was detected in one strain (1.6%), of
850 bp in two strains (3.3%), of 800 bp in 14 (23%), and
of 650 bp in 43 strains (70.5%). No PCR product was
detected in one MRSA strain. Eleven differently sized PCR
products were identified in MSSA strains. PCR amplifica-
tion of the 3' end of the coagulase gene revealed a single
amplicon in 34 of the 37 strains, which ranged between
480 bp and 950 bp. Two PCR amplicons of 400 bp, 750
bp were detected in one strain and of 400 bp, 1000 bp in
Table 1: Antibiotic susceptibility of S. aureus isolates (MSSA and MRSA) from KZN province, South Africa
MSSA n = 166 MRSA n = 61 Total n = 227
Antibiotic Number of isolates 
that were:
Resistance 
rate (%)
Number of isolates 
that were:
Resistance 
rate (%)
No/Resistance 
rate (%)
SR SR
Penicillin 19 147 88.6 0 61 100 208 (91.6)
Ampicillin 19 147 88.6 0 61 100 208 (91.6)
Oxacillin 166 0 0 0 61 100 61 (26.9)
Erythromycin 147 19 11.4 11 50 82 69 (30.4)
Clindamycin 148 18 10.8 11 50 82 68 (30.0)
Gentamicin 160 6 3.6 2 59 96.7 65 (28.6)
Streptomycin 166 0 0 42 19 31.1 19 (8.4)
Kanamycin 160 6 3.6 2 59 96.7 65 (28.6)
Neomycin 166 0 0 42 19 31.1 19 (8.4)
Trimethoprim 148 18 10.8 9 52 85.2 70 (30.8)
Trimethoprim/Sulphamethoxazole 148 18 10.8 9 52 85.2 70 (30.8)
Tetracycline 153 13 7.8 6 55 90.2 68 (30.0)
Minocycline 166 0 0 6 55 90.2 55 (24.2)
Teicoplanin 166 0 0 61 0 0 0
Vancomycin 166 0 0 61 0 0 0
Chloramphenicol 165 1 0.6 51 10 16.4 11 (4.8)
Ciprofloxacin 165 1 0.6 50 11 18.0 12 (5.3)
Fusidic acid 166 0 0 61 0 0 0
Rifampicin 165 1 0.6 16 45 73.8 46 (20.3)
Mupirocin (5 µg) 165 1 0.6 46 15 24.6 16 (7.0)
Mupirocin (200 µg) 165 1 0.6 60 1 1.6 2 (0.9)
Methicillin ND ND - 0 61 100 -
Cefoxitin ND ND - 0 61 100 -
KEY
S – sensitive; R – Resistant.
ND: Not DeterminedBMC Infectious Diseases 2006, 6:125 http://www.biomedcentral.com/1471-2334/6/125
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two strains. A single amplicon of 480 bp was detected in
one strain and of 600 bp, 650 bp, 700 bp and 950 bp in
two strains respectively. PCR products of 850 bp (five
strains), of 750 bp and 900 bp (six strains), and 800 bp
(seven strains) were also identified. No PCR product was
detected in one MSSA strain. Overall, a single fragment of
650 bp was detected in 45 S. aureus strains (MSSA and
MRSA), followed by 800 bp in 21 strains, of 750 bp and
850 bp in seven strains and 900 bp in six strains.
A total of 11 distinct RFLP patterns (types 1a–11a) were
observed among 96 strains examined after AluI digestion
of the PCR products (Table 3). Two additional strains
(one MSSA and one MRSA) failed to yield a product with
the primers and were therefore classified as twelfth type
(12a). The strains belonging to type 7 were subdivided
into seven subtypes; group 8 into five subtypes, types 3
and 5 into four subtypes and types 2, 4 and 9 into two
subtypes respectively. The 61 MRSA strains were classified
into five main RFLP patterns (types 3, 5, 7, 8 and 12) and
most of the strains (67.2%) were grouped in subtype 3a.
The 37 MSSA strains were categorized into 12 genotypes,
and two MSSA in subtype 5b shared similar RFLP patterns
with one of the MRSA strains.
The association between antibiotyping and PCR-RFLP of
the coagulase gene in MRSA from South Africa is
described in Table 4. Nine antibiotypes were noted for
Table 2: Antibiotyping of S. aureus isolates (MSSA and MRSA) from KZN province, South Africa.
MRSA (n = 61) No. of MRSA (%)**
Antibiotype* Resistance patterns
PEN GM EM TE TM CIP MUP CHL RF
1 + + + + + + + + 4 (6.6)
2 + + + + + + + 1 (1.6)
3 + + + + + + + 3 (4.9)
4 + + + + + + + 4 (6.6)
5 + + + + + + + 6 (9.8)
6 + + + + + + 2 (3.3)
7 + + + + + + 2 (3.3)
8 + + + + + + 25 (41.0)
9 + + + + + 1 (1.6)
10 + + + + + 5 (8.2)
11 + + + 2 (3.3)
12 + + + 6 (9.8)
MSSA (n = 166)
PEN GM EM TE TM CIP MUP CHL RF
1 + + + + 1 (0.6)
2 + + + + 1 (0.6)
3 + + + + 4 (2.4)
4 + + + 1 (0.6)
5 + + + 1 (0.6)
6 + + + 1 (0.6)
7 + + + 2 (1.2)
8 + + + 3 (1.8)
9 + + + 5 (3.0)
10 + + 1 (0.6)
11 + + 2 (1.2)
12 + + 3 (1.8)
13 + + 9 (5.4)
14 + 114 (68.7)
15 SUSCEPTIBLE TO ALL ANTIBIOTICS 18 (10.8)
KEY
PEN: Penicillin; GEN: Gentamicin; EM: Erythromycin; TE: Tetracycline; TM: Trimethoprim; CIP: Ciprofloxacin; MUP: Mupirocin (5 µg); CHL: 
Chloramphenicol; RF: Rifampicin.
* Number of antibiotypes in MRSA and MSSA isolates.
** Percentages in parentheses are based on the total number of isolates in each group (MRSA n = 61; MSSA n = 166).BMC Infectious Diseases 2006, 6:125 http://www.biomedcentral.com/1471-2334/6/125
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MRSA in type 3a (PCR-RFLP: 650 bp; 81, 567 bp) and
88% of strains in the predominant antibiotype 8 were
grouped in PCR-RFLP subtype 3a. In addition, five of the
six MRSA strains in antibiotype 12 and five of the six
MRSA assigned to antibiotype 5 belonged to PCR-RFLP
types 7a and 7b respectively. Furthermore, the four strains
in antibiotype 1 were equally shared between types 7b
and 7c.
Discussion
Antimicrobial resistance has been noticed as one of the
paramount microbial threats of the twenty-first century
[35]. S. aureus has always been a stumbling block for anti-
microbial chemotherapy and the introduction of new
classes of antimicrobial agents is usually followed by the
emergence of resistant forms of this pathogen [16,36].
Therefore, surveillance on the antimicrobial susceptibility
patterns of S. aureus is of utmost importance in under-
standing new and emerging resistance trends and in the
management of both hospital and community-acquired
infections.
In this study, all the isolates were susceptible to teico-
planin, vancomycin and fusidic acid, while penicillin and
ampicillin were the least effective antimicrobial agents.
Although the disk diffusion technique utilized in this
study for the determination of susceptibility to vancomy-
cin and teicoplanin is unreliable due to its low sensitivity
[37], isolates that exhibited resistance to oxacillin were
screened for intermediate resistance to vancomycin and
teicoplanin using the E-test macrodilution method [28].
None of the MRSA demonstrated resistance to these anti-
biotics. The susceptibility patterns of S. aureus isolates in
this study were compared with data from an international
multi-centre study, in which 21 laboratories in 18 coun-
tries (including South Africa) participated [38]. The full
susceptibility of S. aureus to fusidic acid observed in this
study agreed with data from the multi-centre survey, indi-
cating that fusidic acid is an excellent and effective agent
for the treatment of S. aureus infections in South Africa.
However, monotherapy with fusidic acid has been associ-
ated with the emergence of resistance; therefore it is usu-
ally combined with another antistaphylococal agent
(beta-lactams, rifampicin or glycopeptides) to minimize
the emergence of fusidic-acid resistant strains [39]. The
prevalence of S. aureus resistance to rifampicin, erythro-
mycin, clindamycin, and tetracycline noted in this study
was also comparable with data from the multi-centre
PCR-RFLPs of the coagulase gene in MRSA strains from South Africa showing various types: Lanes 1: 100 bp molecular weight  markers Figure 1
PCR-RFLPs of the coagulase gene in MRSA strains from South Africa showing various types: Lanes 1: 100 bp molecular weight 
markers. Lane 2: Type 5b; Lane 3: 3a; Lanes 4 and 5: 7b; Lane 6: 7a; Lane 7: 3b
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study (South Africa). However, resistance to ciprofloxacin
was lower in this investigation (5.3% vs 29%) compared
with the multi-centre survey.
Since the emergence of the first clinical isolate of MRSA
was reported in 1961, this pathogen has posed challenges
in the treatment of infections in which its characteristic
nature of multi-drug resistance restricts the options to
treat infections [40-42]. One of the earliest reports of
MRSA in South Africa was reported in a Durban hospital
[17]. Of the 227 S. aureus isolates obtained in this study in
the KZN province of South Africa, 61 (26.9%) were con-
firmed as MRSA. The prevalence of MRSA was lower than
previous reports in major cities in South Africa such as
Johannesburg and Cape Town, which ranged between
33% and 43% [7,38,43-45]. However, the prevalence of
MRSA in hospitals within the city of Durban was 34%,
which is comparable with previous data in major cities in
South Africa. A limitation in this study was that a compar-
ative analysis of MRSA based on the geographic location
of the health institutions could not be determined due to
the low and varying numbers obtained in the various
health institutions. Based on the level of resistance and
grouping as described in the multi-centre study [38], S.
aureus resistance to oxacillin along with gentamicin, kan-
amycin, tetracycline, minocycline, erythromycin, clin-
damycin, rifampicin, and trimethoprim could be
considered to be of concern in KZN province, South
Africa.
There was a relationship between methicillin resistance
and resistance to other antibiotics as noted in previous
investigations [16,38,43,46]. This study also supports the
observation of a relationship between oxacillin and
aminoglycoside resistance in S. aureus [16,47]. More than
90% of MRSA were resistant to gentamicin and kanamy-
cin whereas less than 4% of MSSA were resistant to these
aminoglycosides. While the frequency of MRSA resistance
to the tetracyclines (tetracycline and minocycline) was
high (90.2%), in-vitro resistance to minocycline was not
observed in MSSA and only 7.8% were resistant to tetracy-
cline. Resistance to rifampicin by MSSA was less than 1%
while MRSA resistance was 74%.
A major problem in the treatment of S. aureus infections
is the ability of this pathogen to be resistant to a number
of antibiotics. In the last few years, understanding of the
genetic basis for methicillin resistance has advanced sig-
nificantly. Staphylococcal cassette chromosome mec (SCC
mec) elements are, so far, the only vectors described for
the mecA gene encoding resistance in staphylococci [48].
As well as resistance to all beta-lactams, the SCC mec can
encode resistance to bleomycin, macrolide-lincosamide-
streptogramin B, aminoglycosides (tobramycin, ami-
kacin), and spectinomycin [49]. Multi-resistant MRSA has
been reported to be relatively high in African countries
including Morocco, Kenya, Nigeria and Cameroun [50],
but their antibiotypes were not determined. In this study,
MRSA were grouped into 12 antibiotypes and 87% were
resistant to at least four classes of antibiotics. In addition,
isolates belonging to antibiotype 8 were identified in 12
of the 14 hospitals, indicating that MRSA with this resist-
ance phenotype appears to be widespread in KZN. MRSA
classified in antibiotypes 1 and 5 (resistance to eight and
seven classes of antibiotics respectively) were identified in
health institutions located in Durban, Pietermaritzburg
(Western KZN) and Ngwelezane (Northern KZN). This
study confirms the multi-resistant nature of healthcare-
associated MRSA as reported by previous investigations
from various regions of the world [16,46,51,52]. It also
indicates that treatment of infections caused by health-
care-associated MRSA may be difficult in this province, as
PCR-RFLPs of the coagulase gene in MSSA strains from South Africa showing the various types: Lanes 1 and 19: 100 bp molec- ular weight markers Figure 2
PCR-RFLPs of the coagulase gene in MSSA strains from South Africa showing the various types: Lanes 1 and 19: 100 bp molec-
ular weight markers. Lane 2: Type 1a; Lane 3: 2b; Lane 4: 2a; Lane 5: 3d; Lane 6: 3c; Lane 7: 4a; Lane 8: 4b; Lane 9: 5b; Lane 10: 
5d; Lane 11: 5a; Lane 12: 5c; Lane 13: 6a; Lane 14: 7d; Lane 15: 7e; Lane 16: 7g; Lane 17: 7c; Lane 18: 8b
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there are reduced antimicrobial options, which could lead
to substantial rates in morbidity and mortality in hospital
patients and increased health cost.
About 65% of S. aureus susceptible to erythromycin and
clindamycin were MSSA, while the inducible MLSB pheno-
type was detected in 10.8% of MSSA and 82% of MRSA
respectively. A recent survey in Pennsylvania, USA,
observed that 68% of MSSA and 12.3% of MRSA were D-
test positive [53]. In our study, the constitutive MLSB phe-
notype was identified in one MSSA isolate, but absent in
all the MRSA. This trend is in contrast to the report in
Korea whereby 24% of MSSA and 86% of MRSA exhibited
constitutive resistance [16]. Furthermore, the constitutive
MLSB phenotype is known to be a common feature among
MRSA isolates in Belgium [54] and Greece [55]. These
observations indicate that the incidence of constitutive
and inducible MLSB resistance in staphylococcal isolates
varies by geographic region. The D-test was demonstrated,
like previous studies, to be a simple and reliable method
to detect inducible resistance to clindamycin. In January
2004, the National Committee for Clinical Laboratory
Standards (now CLSI) published a procedure for clin-
damycin induction testing [56]. The clinical microbiology
laboratories in South Africa should consider routine test-
ing and reporting of inducible clindamycin resistance in
S. aureus. This is to ensure that clinicians can rely on clin-
damycin test results and be informed about the possibility
of clindamycin treatment failure in patients with infec-
tions caused by inducibly resistant isolates. The propor-
tion of MRSA with the inducible MLSB phenotype (82%)
indicates that clindamycin may not be a theraupeutic
option for the treatment of an infection attributed to an
inducibly resistant MRSA. If clindamycin is used for treat-
Table 3: PCR-RFLP of the coagulase gene in MSSA and MRSA strains from South Africa
AluI restriction fragments
Type Molecular weight 
(± 20 bp)
Total number 
of strains
mecA-positive mecA-negative 81 162 243 324 405 486 567 648 729 810
1a 480 1 0 1 + +
2a 600 1 0 1 + +
2b 1 0 1 + +
3a 650 41 41 0 + +
3b 2 2 0 +
3c 1 0 1 + +
3d 1 0 1 + +
4a 700 1 0 1 + + +
4b 1 0 1 + + +
5a 750 1 0 1 + + +
5b 3 1 2 + + +
5c 1 0 1 + + +
5d 2 0 2 + + +
6a 750, 400 1 0 1 + + +
7a 800 5 5 0 + + +
7b 7 7 0 + + +
7c 2 2 0 + +
7d 2 0 2 + + +
7e 3 0 3 + + +
7f 1 0 1 + +
7g 1 0 1 +
8a 850 1 1 0 + + +
8b 1 0 1 + + +
8c 2 0 2 + + +
8d 2 0 2 + +
8e 1 1 0 + +
9a 900 5 0 5 + + +
9b 1 0 1 + + +
10a 950 2 0 2 + + +
11a 1000, 400 2 0 2 + + + +
12a No product 2 1 1
Total 98 61 37BMC Infectious Diseases 2006, 6:125 http://www.biomedcentral.com/1471-2334/6/125
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ment of infections with MLSBi-positive isolates, close fol-
low-up and monitoring of failure or relapse is needed.
However, in more severe infections, the presence of the
MLSBi phenotype should preclude the use of clindamycin.
Our study observed a high prevalence of rifampicin resist-
ance (73.8%) among the MRSA, suggesting that this trend
may be increasing worldwide. Rifampicin resistance in S.
aureus has been reported in Australia [57], United King-
dom [58], Malaysia [59], Turkey [60] and Poland [61].
Furthermore, a recent study on MRSA in eight African
countries noted that the prevalence of rifampicin resist-
ance was high with the exception of two countries
(Morocco and Kenya) [50]. Resistance to rifampicin has
been reported to be a common trend among S. aureus in
South Africa [44] and clinical isolates of Mycobacterium
tuberculosis  [62]. This could be attributed to the wide-
spread use of this antimicrobial agent. Interestingly, a
high level of rifampicin resistance has also been observed
in environmental isolates of members of the family
Enterobacteriaceae in Northern KZN [63]. These facts indi-
cate the severity of rifamipicin resistance in both clinical
and environmental bacteria in this province and probably
in South Africa as a whole.
Parenteral glycopeptides (vancomycin and teicoplanin)
are the mainstay of therapy for MRSA infections. How-
ever, rifampicin, fusidic acid, ciprofloxacin and trimetho-
prim-sulfamethoxazole (TMP-SMX) are widely used oral
agents that have demonstrated consistent in-vitro activity
and are recommended in the therapy of MRSA infections
[16,57,64]. Combination therapy with two oral agents is
thought to be important to decrease the risk of selecting
for mutants during therapy of MRSA infections [64-67]. In
Australasia, rifampicin and fusidic acid are the usual com-
bination to treat MRSA infections [64,68], while in the
United States, TMP-SMX is claimed to be widely used,
with or without rifampicin, for MRSA infections that are
not life-threatening [69]. This study observed that 73.8%
and 85.2% of MRSA were resistant to rifampicin and TMP-
SMX respectively. Although we did not investigate the
level of usage regarding TMP-SMX and rifampicin in these
hospitals, combination treatment with these antibacterial
agents would be unreliable in KZN, South Africa.
Resistance to mupirocin was detected in 16 S. aureus iso-
lates and 94% were MRSA. The prevalence of mupirocin
resistance in this study (7%) was higher than a previous
study (2%) in South Africa [38]. However, high-level
mupirocin resistance by S. aureus in our study was lower
than surveys conducted in Greece [70,71], South Korea
[72] and Poland [73]. One MSSA and one MRSA were
mupA positive, while all the isolates with low-level mupi-
rocin resistance (mupA negative) were MRSA. This trend
suggests that mupirocin resistance in S. aureus is an emerg-
ing feature in this province, particularly in Durban. To the
best of our knowledge, this is the first report of S. aureus
resistance to mupirocin in this province. Inspite of the
Table 4: Correlation between PCR-RFLP of the coagulase gene and antibiotyping of MRSA strains from South Africa
Type (PCR-RFLP coagulase gene) ± 20 
bp (number of strains)
Antibiotype (number of strains)
PEN GM EM TE TM CIP MUP CHL RF
3a 650 (81, 567) (41) + + + + + + + (1)
++ + + + + +  ( 3 )
++ + + + ++  ( 4 )
++ + + ++  ( 2 )
++ + + + +  ( 2 )
++ + + + +  ( 2 2 )
++ + + +  ( 1 )
++ + + +  ( 4 )
++ +  ( 2 )
3b 650 (567) (2) + + + + + + (1)
++ + + +  ( 1 )
5b 750 (81, 243, 405) (1) + + + + + + (1)
7a 800 (81, 162, 486) (5) + + + (5)
7b 800 (81, 324, 405) (7) + + + + + + + + (2)
++ + + + + + ( 5 )
7c 800 (324, 405) (2) + + + + + + + + (2)
8a 850 (81, 162, 486) (1) + + + (1)
8e 850 (324, 405) (1) + + + + + + + (1)
12a No product (1) + + + + + + (1)BMC Infectious Diseases 2006, 6:125 http://www.biomedcentral.com/1471-2334/6/125
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small amount of data on mupirocin resistance in MSSA, it
is suggested that MRSA along with MSSA should be rou-
tinely tested in clinical microbiology laboratories in this
province so that resistant isolates could be detected early,
and to facilitate the prompt institution of infection con-
trol measures.
Coagulase is produced by strains of S. aureus [74]. Its pro-
duction is the principal criterion used in the clinical
microbiology laboratory for the identification of S. aureus
in human infections [75]. The coagulase gene has been a
target for PCR genotyping in which size and DNA restric-
tion endonuclease site polymorphism within the coa gene
have been utilized for PCR-RFLP analysis [76]. Coagulase
gene typing has been reported to be an attractive method
for clinical laboratories because of its ease and speed, and
has been widely used in genotyping of clinical S. aureus
isolates [33,77-83].
Results of coagulase gene typing demonstrated that the
MRSA and MSSA strains from South Africa were classified
into four and eleven RFLP patterns, respectively. However,
two strains (one MSSA and one MRSA) failed to yield a
PCR product with the primers. The inability for a gene
product to be obtained could be due to sequence varia-
tions at the sites targeted by the primers, as described by
some investigators [75,83,84]. A total of 67% of MRSA
were classified into the subtype 3a, indicating that strains
with this profile were predominant in health institutions
in KZN province, South Africa. In contrast, the MSSA
strains were diverse and none of the RFLP patterns could
be considered as a predominant group. This finding is
similar to previous studies [33,78]. It also indicates that
genomic variation was lower in MRSA than in MSSA
strains. The ability of the PCR-RFLP of the coagulase gene
to differentiate between MRSA and MSSA from South
Africa was also observed. The MSSA and MRSA strains did
not share similar PCR-RFLP patterns in types 3, 7 and 8,
while none of the MRSA strains were identified in types 1,
2, 4, 6, 9, 10 and 11. The RFLP patterns of the MRSA
strains were unique and distinct from the MSSA strains,
but two MSSA in subtype 5b shared similar PCR-RFLP pat-
terns with one of the MRSA strains. The ability of the PCR-
RFLP to distinguish MSSA from MRSA strains has been
reported [79], and offers an attractive option to be consid-
ered in the epidemiological analysis of S. aureus in South
Africa. Some degree of correlation between the two typing
methods was observed. A good correlation between anti-
biotyping and PCR-RFLP of the coagulase gene was
observed in identifying strains within antibiotype 12.
Only one strain in antibiotype 12 (PCR-RFLP group 8a)
produced a differently sized amplicon by PCR detection
of the coagulase gene, but the RFLP pattern was similar
with the rest of the strains in PCR-RFLP group 7a. All the
ten multi-drug resistant MRSA strains assigned in antibio-
type groups 1 and 5 produced similar PCR-RFLP patterns
indicating that they were closely related.
Conclusion
This study has provided baseline information in assisting
physicians, clinical microbiologists and public health offi-
cials on critical issues regarding empirical and pathogen
specific therapy. The isolation of multi-resistant MRSA in
various health facilities, the wide dissemination of MRSA
grouped in antibiotype 8 and the emerging trend of mupi-
rocin resistance indicate that adequate steps in limiting
spread are urgently needed. Continuous surveillance on
resistance patterns of S. aureus in understanding new and
emerging trends is of utmost importance. PCR-RFLP of
the coagulase gene represents an attractive tool for the
rapid initial genotyping of S. aureus in South Africa.
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